- In May 2025, QIAGEN Expands Digital PCR Oncology Research Portfolio through Partnership with ID Solutions. QIAGEN announced a commercial partnership and co-marketing agreement with ID Solutions, a French provider of high-quality digital PCR (dPCR) assays. This collaboration aims to expand QIAGEN's dPCR oncology research portfolio by offering optimized assays for multi-mutation detection on QIAGEN's QIAcuity platforms, reinforcing its commitment to comprehensive dPCR solutions
- In May 2025, QIAGEN Launches Digital PCR Lentivirus Solutions for Cell and Gene Therapy Quality Control. QIAGEN announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPCR) workflow that now includes solutions for lentivirus-based applications, commonly used in the production of advanced treatments such as CAR-T cell therapy. These solutions support high-precision quality control workflows
- In July 2024, Bio-Rad Launches New ddPCR Methylation Detection Assays. Bio-Rad launched more than 50 new ddPCR Methylation Detection Assays, available on its Digital Assays portal. These assays are designed to provide more precise and reliable detection of methylation markers crucial for early diagnosis and monitoring of various cancers, further expanding Bio-Rad's Droplet Digital PCR platform into life science research and clinical diagnostics
- In May 2024, Thermo Fisher Scientific Organizes 2024 Digital PCR Workshop Series. Thermo Fisher Scientific is conducting a series of digital PCR workshops in 2024 to provide an overview of dPCR technology, key benefits of the QuantStudio Absolute Q dPCR System, and hands-on experience. This initiative aims to educate users on dPCR applications in various fields such as gene expression, copy number variation, and cancer research
- In May 2024, Roche Diagnostics to Introduce New Molecular Lab Solutions. Roche is set to introduce new molecular lab solutions in 2024, including upgrades for its cobas 6800/8800 systems with increased testing flexibility, throughput, and automation. These developments highlight Roche's commitment to advancing its molecular diagnostics portfolio and leveraging new technologies for efficient testing
